Screening for Gastric Cancer in High-risk Population (Stomach)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00815113|
Recruitment Status : Recruiting
First Posted : December 29, 2008
Last Update Posted : September 7, 2017
Introduction: Gastric cancer is the world's second largest cause of cancer related deaths. In the Western world, as well as in Israel, this malignancy is less prevalent than colorectal cancer, but has higher morbidity and mortality. First degree relatives of patients with gastric cancer have a 1.5-fold to 3-fold increased risk of developing gastric cancer themselves. In relatives of gastric cancer patients who are also carriers of a CagA positive strain of Helicobacter pylori, the risk is 8-fold. Mucosal atrophy, hypochlorhydria, high lymphoid follicle density, pan gastritis, and interleukin 1 β polymorphism are frequent in family members of gastric cancer patients and are associated with increased risk of the disease.
- To characterize the high risk individual for gastric cancer development.
- To establish a screening plan for early detection and prevention of gastric cancer in first degree relatives of gastric cancer patients.
- To validate new procedures for assessing risk factors for development of gastric cancer: gastric acid output, gastric mucin output, serum levels of pepsinogen I, pepsinogen II, gastrin B12, Helicobacter pylori status [serology, histology, urease test, 13C-urea breath test (13C-UBT)].
- To assess genetic changes in the gastric mucosa of the screenees in comparison with gastric cancer patients and controls.
We will approach 50 gastric cancer patients treated in Rabin Medical Center, and ask for their consent to approach first degree relatives for participating in the study. For each gastric cancer patient 4 relatives will be asked to signed an informed consent and undergo the study procedures. For each participant a matched control for age, sex and background diseases, out of consecutive gastro esophageal reflux disease (GERD) patients undergoing gastroscopy, will be asked to join the study. Thus, we will screen 50 gastric cancer patients, 200 first degree relatives of gastric cancer patients, and 200 controls.
|Condition or disease|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Screening for Gastric Cancer in High-risk Population|
|Actual Study Start Date :||October 2009|
|Estimated Primary Completion Date :||January 2018|
|Estimated Study Completion Date :||January 2018|
First degree relative of gastric cancer patient
Consecutive gastro-esophageal reflux patients
- Characterization of the high-rik individual for gastric cancer - "Gastric Cancer Phenotype" [ Time Frame: 2 years ]
- Establish a screen plan for high-risk population for gastric cancer [ Time Frame: 2 years ]
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00815113
|Contact: Tami lederfien, BScemail@example.com|
|Contact: Yaron Niv, MDfirstname.lastname@example.org|
|Department of Gastroenterology, Rabin Medical Center||Recruiting|
|Petach Tikva, Israel, 49100|
|Contact: Tami Lederfein, BSc 97239377040 email@example.com|
|Contact: Yaron Niv, MD 97239377237 firstname.lastname@example.org|
|Principal Investigator: Yaron Niv, MD|
|Principal Investigator:||Yaron Niv, MD||RMC|